CohBar (NASDAQ:CWBR) Rating Lowered to Hold at Brookline Capital Management

CohBar (NASDAQ:CWBR – Get Rating) was downgraded by research analysts at Brookline Capital Management from a “buy” rating to a “hold” rating in a research report issued on Wednesday, PriceTargets.com reports.

CohBar Stock Down 2.3 %

NASDAQ:CWBR opened at $1.71 on Wednesday. CohBar has a twelve month low of $1.50 and a twelve month high of $15.60. The firm has a market capitalization of $4.97 million, a price-to-earnings ratio of -0.41 and a beta of 1.97. The stock’s 50 day moving average price is $2.15 and its two-hundred day moving average price is $4.79.

CohBar (NASDAQ:CWBR – Get Rating) last announced its quarterly earnings results on Tuesday, November 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.02) by $0.20. As a group, analysts anticipate that CohBar will post -3.78 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in CohBar stock. Millennium Management LLC raised its position in CohBar, Inc. (NASDAQ:CWBR – Get Rating) by 241.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 208,603 shares of the company’s stock after buying an additional 147,442 shares during the quarter. Millennium Management LLC owned about 0.24% of CohBar worth $40,000 at the end of the most recent quarter. 7.85% of the stock is owned by institutional investors.

About CohBar

(Get Rating)

CohBar, Inc, a clinical stage biotechnology company, focuses in the research and development of mitochondria based therapeutics (MBTs) for the treatment of chronic and age-related diseases. The company develops MBTs to treat non-alcoholic steatohepatitis (NASH), obesity, fatty liver disease, idiopathic pulmonary fibrosis, type 2 diabetes, acute respiratory distress syndrome, cancer, and cardiovascular diseases, such as Alzheimer's disease.